These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 26888996)

  • 1. Testing HLA-B*15:02: Is it worth it?
    Marson A; Guerrini R
    Neurology; 2016 Mar; 86(12):1080-1. PubMed ID: 26888996
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-world cost-effectiveness of pharmacogenetic screening for epilepsy treatment.
    Chen Z; Liew D; Kwan P
    Neurology; 2016 Mar; 86(12):1086-94. PubMed ID: 26888992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical considerations for pharmacogenetic testing.
    Wedlund PJ
    MLO Med Lab Obs; 2001 Sep; 33(9):16-21, 23; quiz 24-5. PubMed ID: 11569125
    [No Abstract]   [Full Text] [Related]  

  • 4. Scanning the human genome and the horizon: the potential and pitfalls of pharmacogenetics and stratified medicine.
    Jennings BA; Shakespeare T; Loke YK
    Br J Gen Pract; 2015 Jun; 65(635):284-5. PubMed ID: 26009508
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacogenetics and cost-effectiveness analysis: a two-way street.
    Chalkidou K; Rawlins M
    Drug Discov Today; 2011 Oct; 16(19-20):873-7. PubMed ID: 21903176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of the pharmacoeconomics of pharmacogenetics.
    Dervieux T; Bala MV
    Pharmacogenomics; 2006 Dec; 7(8):1175-84. PubMed ID: 17184205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.
    Yeo SI
    Int J Rheum Dis; 2013 Jun; 16(3):254-7. PubMed ID: 23981744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Useless until proven effective: the clinical utility of preemptive pharmacogenetic testing.
    Janssens AC; Deverka PA
    Clin Pharmacol Ther; 2014 Dec; 96(6):652-4. PubMed ID: 25399713
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore.
    Hung SI; Chung WH
    Neurology; 2013 Apr; 80(17):1621. PubMed ID: 23610150
    [No Abstract]   [Full Text] [Related]  

  • 10. The value of routine pharmacogenomic screening-Are we there yet? A perspective on the costs and benefits of routine screening-shouldn't everyone have this done?
    Veenstra DL
    Clin Pharmacol Ther; 2016 Feb; 99(2):164-6. PubMed ID: 26565561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost of exome sequencing in epileptic encephalopathy: is it 'worth it'?
    Forman EB; Gorman KM; Conroy J; Arthur N; Grant C; Ennis S; Allen NM; Lynch SA; King MD
    Arch Dis Child; 2018 Mar; 103(3):304. PubMed ID: 28939639
    [No Abstract]   [Full Text] [Related]  

  • 12. Systematic review of pharmacoeconomic studies of pharmacogenomic tests.
    Beaulieu M; de Denus S; Lachaine J
    Pharmacogenomics; 2010 Nov; 11(11):1573-90. PubMed ID: 21121811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders.
    Serretti A; Olgiati P; Bajo E; Bigelli M; De Ronchi D
    World J Biol Psychiatry; 2011 Oct; 12(7):501-15. PubMed ID: 21595526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stratified medicine: making it happen.
    Foot E
    Drug Discov Today; 2011 Oct; 16(19-20):848-9. PubMed ID: 21920455
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of genetic testing in epilepsy diagnosis and management.
    Weber YG; Biskup S; Helbig KL; Von Spiczak S; Lerche H
    Expert Rev Mol Diagn; 2017 Aug; 17(8):739-750. PubMed ID: 28548558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic yield of targeted massively parallel sequencing in children with epileptic encephalopathy.
    Kothur K; Holman K; Farnsworth E; Ho G; Lorentzos M; Troedson C; Gupta S; Webster R; Procopis PG; Menezes MP; Antony J; Ardern-Holmes S; Dale RC; Christodoulou J; Gill D; Bennetts B
    Seizure; 2018 Jul; 59():132-140. PubMed ID: 29852413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The future of pharmacogenetics--cost-effectiveness and barriers].
    Gyrd-Hansen D
    Ugeskr Laeger; 2005 May; 167(20):2153-5. PubMed ID: 15987071
    [No Abstract]   [Full Text] [Related]  

  • 18. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine.
    Marra CA; Esdaile JM; Anis AH
    J Rheumatol; 2002 Dec; 29(12):2507-12. PubMed ID: 12465143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions.
    Ke CH; Chung WH; Wen YH; Huang YB; Chuang HY; Tain YL; Wang YL; Wu CC; Hsu CN
    J Rheumatol; 2017 Jun; 44(6):835-843. PubMed ID: 28365572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Financial determinants of outcomes in molecular testing.
    Ross JS
    Arch Pathol Lab Med; 1999 Nov; 123(11):1071-5. PubMed ID: 10539911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.